NLNicolas Lerolle

Nicolas Lerolle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicolas Lerolle has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of renal hemodynamic toxicity of fluid challenge with 0.9% NaCl compared to balanced crystalloid (PlasmaLyte®) in a rat model with severe sepsis

    by Pierre-Yves Olivier, François Beloncle, Valérie Seegers, Maher Tabka, Mathilde Renou de La Bourdonnaye, Alain Mercat, Paul Cales, Daniel Henrion, Peter Radermacher, Lise Piquilloud, et al.


  • Open Access

    Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomized controlled trial (AKIKI)

    by Stéphane Gaudry, David Hajage, Fréderique Schortgen, Laurent Martin-Lefevre, Florence Tubach, Bertrand Pons, Eric Boulet, Alexandre Boyer, Nicolas Lerolle, Guillaume Chevrel, et al.

    There is currently no validated strategy for the timing of renal replacement therapy (RRT) for acute kidney injury (AKI) in the intensive care unit (ICU) when short-term life-threatening metabolic abnormalities are absent. No adequately powered prospective randomized study has addressed this issue to date. As a result, significant practice heterogeneity exists and may expose patients to either unnecessary hazardous procedures or undue delay in RRT. This is a multicenter, prospective, randomized, open-label parallel-group clinical trial that compares the effect of two RRT initiation strategies on overall survival of critically ill patients receiving intravenous catecholamines or invasive mechanical ventilation and presenting with AKI classification stage 3 (KDIGO 2012). In the ‘early’ strategy, RRT is initiated immediately. In the ‘delayed’ strategy, clinical and metabolic conditions are closely monitored and RRT is initiated only when one or more events (severity criteria) occur, including: oliguria or anuria for more than 72 hours after randomization, serum urea concentration >40 mmol/l, serum potassium concentration >6 mmol/l, serum potassium concentration >5.5 mmol/l persisting despite medical treatment, arterial blood pH 5 l/min to maintain SpO2 > 95% or FiO2 > 50% under invasive or noninvasive mechanical ventilation. The primary outcome measure is overall survival, measured from randomization (D0) until death, regardless of the cause. The minimum follow-up duration for each patient will be 60 days. Two interim analyses are planned, blinded to group allocation. It is expected that there will be 620 subjects in all. The AKIKI study will be one of the very few large randomized controlled trials evaluating mortality according to the timing of RRT in critically ill patients with AKI classification stage 3 (KDIGO 2012). Results should help clinicians decide when to initiate RRT. ClinicalTrials.gov NCT01932190 .


  • Open Access

    Comparaison n’est pas raison, mais quand même...

    by N. Lerolle

  • Open Access

    Does vasopressor therapy have an indication in hemorrhagic shock?

    by François Beloncle, Ferhat Meziani, Nicolas Lerolle, Peter Radermacher, Pierre Asfar


  • Conséquences hémodynamiques de l’embolie pulmonaire

    by N. Chudeau, N. Lerolle, J. -L. Diehl, A. Mercat

    L’embolie pulmonaire (EP) grave est définie par la survenue d’une défaillance ventriculaire droite secondaire à une augmentation de postcharge. L’existence d’une hypotension, de signes périphériques de choc et/ou de signes de dysfonction ventriculaire droite est associée à une surmortalité. Les interactions entre les anomalies vasculaires pulmonaires, les fonctions ventriculaires droite et gauche et la circulation coronaire rendent compte des perturbations hémodynamiques observées aux différents stades de l’EP grave. L’échocardiographie permet d’apprécier le retentissement hémodynamique de l’EP, de même que certains indices scannographiques. Ces dernières années, la recherche s’est centrée sur les patients à risque intermédiaire, c’està-dire non hypotendus mais présentant des signes échographiques de dysfonction ventriculaire droite ainsi qu’une élévation des marqueurs myocardiques (proBNP [brain natriuretic peptide], BNP et troponine). La place des différentes interventions thérapeutiques symptomatiques ou à visée étiologique est discutée. Acute pulmonary embolism is defined by the occurrence of right ventricular failure secondary to an increase in ventricular afterload. The existence of hypotension, peripheral signs of shock and/or right ventricular dysfunction are associated with a mortality excess. The interactions between the pulmonary vascular anomalies, the function of the left and right ventricles and the coronary circulation reflect the haemodynamic changes seen at the different stages of acute pulmonary embolism. Echocardiography allows the haemodynamic consequences of pulmonary embolism to be determined, as well as certain other scan indicators. Over the last few years, research has been focused on patients at intermediate risk, i.e. not hypotensive but presenting with echocardiographic signs of right ventricular dysfunction, as well as an increase in myocardial markers (proBNP [brain natriuretic peptide], BNP and troponin). The place for different symptomatic or etiological therapeutic treatments are discussed.


  • Open Access

    Accuracy and precision of end-expiratory lung-volume measurements by automated nitrogen washout/washin technique in patients with acute respiratory distress syndrome

    by Jean Dellamonica, Nicolas Lerolle, Cyril Sargentini, Gaetan Beduneau, Fabiano Di Marco, Alain Mercat, Jean-Christophe M Richard, Jean-Luc Diehl, Jordi Mancebo, Jean-Jacques Rouby, et al.

    Introduction: End-expiratory lung volume (EELV) is decreased in acute respiratory distress syndrome (ARDS), and bedside EELV measurement may help to set positive end-expiratory pressure (PEEP). Nitrogen washout/washin for EELV measurement is available at the bedside, but assessments of accuracy and precision in real-life conditions are scant. Our purpose was to (a) assess EELV measurement precision in ARDS patients at two PEEP levels (three pairs of measurements), and (b) compare the changes (Δ) induced by PEEP for total EELV with the PEEP-induced changes in lung volume above functional residual capacity measured with passive spirometry (ΔPEEP-volume). The minimal predicted increase in lung volume was calculated from compliance at low PEEP and ΔPEEP to ensure the validity of lung-volume changes. Methods: Thirty-four patients with ARDS were prospectively included in five university-hospital intensive care units. ΔEELV and ΔPEEP volumes were compared between 6 and 15 cm H2O of PEEP. Results: After exclusion of three patients, variability of the nitrogen technique was less than 4%, and the largest difference between measurements was 81 ± 64 ml. ΔEELV and ΔPEEP-volume were only weakly correlated (r 2 = 0.47); 95% confidence interval limits, -414 to 608 ml). In four patients with the highest PEEP (≥ 16 cm H2O), ΔEELV was lower than the minimal predicted increase in lung volume, suggesting flawed measurements, possibly due to leaks. Excluding those from the analysis markedly strengthened the correlation between ΔEELV and ΔPEEP volume (r 2 = 0.80). Conclusions: In most patients, the EELV technique has good reproducibility and accuracy, even at high PEEP. At high pressures, its accuracy may be limited in case of leaks. The minimal predicted increase in lung volume may help to check for accuracy.


  • Top Cited Papers

    Histopathology of septic shock induced acute kidney injury: apoptosis and leukocytic infiltration

    by Nicolas Lerolle, Dominique Nochy, Emmanuel Guérot, Patrick Bruneval, Jean-Yves Fagon, Jean-Luc Diehl, Gary Hill

    Septic shock is one of the leading causes of acute kidney injury. The mechanisms of this injury remain mostly unknown notably because of the lack of data on renal histological lesions in humans. Kidney biopsy was performed immediately post-mortem in consecutive patients who died of septic shock. Comparisons were made with specimens from eight patients who died of trauma on scene and nine ICU patients that died of non-septic causes. Nineteen septic patients were included, 11 were male, and age was 72 ± 12 years. Anuria occurred in all patients 2.2 ± 1.4 days before death. Seven patients had disseminated intravascular coagulation. In all patients we observed (1) acute tubular lesions whose intensity correlated with blood lactate concentration; (2) intense infiltration by leukocytes, mainly monocytic, in glomeruli and interstitial capillaries as compared to controls; (3) presence of tubular cell apoptosis proved by the presence of apoptotic bodies (2.9% of tubular cells) significantly more frequently than in controls and confirmed by TUNEL and activated caspase-3 staining. Arteriolar/arterial thromboses were observed in only 4 of 19 patients, without any association with presence of disseminated intravascular coagulation. Kidney lesions in septic shock go beyond those associated with simple acute tubular injury, notably capillary leukocytic infiltration and apoptosis. Vascular thrombosis, however, did not appear to play a major role in the majority of patients. The extent to which these lesions are specific to sepsis or are common to all multi-organ failure independent of its cause is yet to be elucidated.


  • Open Access

    Pharmacokinetics of epinephrine in patients with septic shock: modelization and interaction with endogenous neurohormonal status

    by Imad Abboud, Nicolas Lerolle, Saik Urien, Jean-Marc Tadié, Françoise Leviel, Jean-Yves Fagon, Christophe Faisy

    Introduction: In septic patients, an unpredictable response to epinephrine may be due to pharmacodynamic factors or to non-linear pharmacokinetics. The purpose of this study was to investigate the pharmacokinetics of epinephrine and its determinants in patients with septic shock.Methods: Thirty-eight consecutive adult patients with septic shock were prospectively recruited immediately before epinephrine infusion. A baseline blood sample (C0) was taken to assess endogenous epinephrine, norepinephrine, renin, aldosterone, and plasma cortisol levels before epinephrine infusion. At a fixed cumulative epinephrine dose adjusted to body weight and under steady-state infusion, a second blood sample (C1) was taken to assess epinephrine and norepinephrine concentrations. Data were analyzed using the nonlinear mixed effect modeling software program NONMEM.Results: Plasma epinephrine concentrations ranged from 4.4 to 540 nmol/L at steady-state infusion (range 0.1 to 7 mg/hr; 0.026 to 1.67 μg/kg/min). A one-compartment model adequately described the data. Only body weight (BW) and New Simplified Acute Physiologic Score (SAPSII) at intensive care unit admission significantly influenced epinephrine clearance: CL (L/hr) = 127 × (BW/70)0.60× (SAPS II/50)-0.67. The corresponding half-life was 3.5 minutes. Endogenous norepinephrine plasma concentration significantly decreased during epinephrine infusion (median (range) 8.8 (1 – 56.7) at C0vs. 4.5 (0.3 – 38.9) nmol/L at C1,P< 0.001).Conclusions: Epinephrine pharmacokinetics is linear in septic shock patients, without any saturation at high doses. Basal neurohormonal status does not influence epinephrine pharmacokinetics. Exogenous epinephrine may alter the endogenous norepinephrine metabolism in septic patients.